TY - JOUR
T1 - Immunotherapy of cancer using interleukin 2
T2 - current status and future prospects
AU - Rosenberg, Steven A.
PY - 1988
Y1 - 1988
N2 - Lymphokine-activated killer (LAK) cells can be isolated as tumor-specific killer cells from a tumor-bearing host, after selective expansion in vitro by culture in interleukin 2 (IL-2). Animal experiments as well as clinical trials have shown that the adoptive transfer of these MHC unrestricted killer cells into tumor bearing hosts can cause the regression of cancer in selected patients. Here, Steven Rosenberg details his group's work on LAK cell therapy, and suggests how the clinical benefits gained so far can be improved upon.
AB - Lymphokine-activated killer (LAK) cells can be isolated as tumor-specific killer cells from a tumor-bearing host, after selective expansion in vitro by culture in interleukin 2 (IL-2). Animal experiments as well as clinical trials have shown that the adoptive transfer of these MHC unrestricted killer cells into tumor bearing hosts can cause the regression of cancer in selected patients. Here, Steven Rosenberg details his group's work on LAK cell therapy, and suggests how the clinical benefits gained so far can be improved upon.
UR - http://www.scopus.com/inward/record.url?scp=0023839370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023839370&partnerID=8YFLogxK
U2 - 10.1016/0167-5699(88)91261-3
DO - 10.1016/0167-5699(88)91261-3
M3 - Review article
C2 - 3076761
AN - SCOPUS:0023839370
VL - 9
SP - 58
EP - 62
JO - Trends in Immunology
JF - Trends in Immunology
SN - 1471-4906
IS - 2
ER -